NCT04857177View on ClinicalTrials.gov

A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration

PHASE3CompletedINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

October 19, 2018

Primary Completion Date

March 17, 2021

Study Completion Date

March 17, 2021

Conditions
Neovascular(Wet) Age Related Macular Degeneration
Interventions
DRUG

CKD-701

CKD-701 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.

DRUG

Lucentis®

Lucentis® (ranibizumab) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY